Levalbuterol tartrate

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种短效 β2 肾上腺素受体激动剂，用于治疗哮喘和慢性阻塞性肺病 (COPD)。

A short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).Asthma Approved(In Vitro):Levalbuterol (10 μM; 24 hours) hydrochloride induces 11β-HSD1 mRNA expression, however, it does not influence 11β-HSD2expression in airway epithelial cells.Levalbuterol (10 μM; 24 hours) hydrochloride significantly reduces both LPS- and TNF-α-induced NF-κB activity while increasing GRE activation in an 11β-HSD1 dependent manner in a transformed mouse airway epithelial cell line.(In Vivo):Levalbuterol (subcutaneous injection; 1 mg/kg; 14 days) hydrochloride significantly decreases pulmonary inflammation in OVA mice, demonstrated a decrease in eosinophilia and IgE.

——

——

Levosalbutamol tartrate

GPCR/G Protein

Adrenergic Receptor

Adrenergic Receptor

Inflammation/Immunology

Asthma

661464-94-4

628.7083

C30H48N2O12

>98% (HPLC)

10 mM in DMSO

CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O.C(C(C(=O)O)O)(C(=O)O)O

1,3-Benzenedimethanol, α1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-, (α1R)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt)

(-20℃)

With Ice Pack

≥ 2 years